Myelodysplastic syndromes: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• TP53 6
• IDH 12
• FLT3 6
• BCL-2 4
• CD19 5
• CD33 3
• RUNX1 0
• CD123 3
• JAK 3
• PARP 0
• TIM-3 0
• ABL1 0
• KMT2A 1
• CD47 0
• NPM1 2
• PD-1 1
• IL-1 2
• NLRP3 1
• ERK 0
• EZH2 0
• NRAS 0
• RAS 0
• SGLT2 1
• AKT 0
• CD20 1
• CD38 2
• CSF1R 2
• GLP-1 0
• IL-6 1
• PD-L1 0
• PI3K 1
• STING 1
• ALK 0
• AMPK 0
• AR 0
• ATM 0
• BCMA 1
• BRAF 0
• BRCA1 0
• BRCA2 0
• BTK 0
• CCR5 0
• CD22 1
• CD40 0
• COX-2 0
• CTNNB1 0
• GPRC5D 1
• GPX4 0
• HIF-1 0
• IL-15 1
• IL-17 0
• KIT 0
• KRAS 0
• MAPK 0
• MYC 0
• PRMT5 0
• RB1 0
• STAT3 0

EU-13 is a filter, not a ranking: it only narrows the list.

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients

  NCT05237713· University of Leipzig· Updated 6 May 2024

  “Slow recruitment. It is not considered likely that the CANFIRE trial will be able to reach the target number of patients. Clinical responders will be further treated within the trial (expected duration: 3 years after stop of enrollment).”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 3
• CRISPR-Cas Systems 3
• Gene Expression Profiling 12
• Exome Sequencing 8
• Proteomics 2
• Metabolomics 1
• Mass Spectrometry 1
• Flow Cytometry 18
• Immunohistochemistry 1
• Liquid Biopsy 1
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 4
• Magnetic Resonance Imaging 8
• Machine Learning 8
• Deep Learning 3
• Cohort Studies 7

• The role of computational pathology in predicting expression of selected immunohistochemical markers.

  Pol J Pathol, Jun 2026

• An open bone marrow megakaryocyte dataset for automated morphologic studies.

  Sci Data, Dec 2025

• Deep learning in bone marrow cytomorphology: advances in segmentation, classification, and clinical translation.

  Med Oncol, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.